Literature DB >> 24681097

AROS has a context-dependent effect on SIRT1.

Tarja Kokkola1, Tiina Suuronen2, Ferdinand Molnár2, Juha Määttä3, Antero Salminen4, Elina M Jarho2, Maija Lahtela-Kakkonen2.   

Abstract

The modulation of protein deacetylase SIRT1 has a vast therapeutic potential in treatment of several aging-associated diseases. Active regulator of SIRT1 (AROS) is a small endogenous protein which was originally reported to activate SIRT1 through a direct interaction in cancer cells. We show that the interaction between the two proteins is weak and does not alter the activity of SIRT1 in non-cancerous human cells. The results of different in vitro SIRT1 activity assays disclosed AROS as an inhibitor of SIRT1. The functional relationship between AROS and SIRT1 proved to be dependent on the biological context and experimental setting.
Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AROS; Protein–protein interaction; SIRT1; Sirtuin; p53

Mesh:

Substances:

Year:  2014        PMID: 24681097     DOI: 10.1016/j.febslet.2014.03.020

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  6 in total

Review 1.  Sirtuin activators and inhibitors: Promises, achievements, and challenges.

Authors:  Han Dai; David A Sinclair; James L Ellis; Clemens Steegborn
Journal:  Pharmacol Ther       Date:  2018-03-22       Impact factor: 12.310

2.  Identification of potential markers for type 2 diabetes mellitus via bioinformatics analysis.

Authors:  Yana Lu; Yihang Li; Guang Li; Haitao Lu
Journal:  Mol Med Rep       Date:  2020-06-26       Impact factor: 2.952

Review 3.  Regulation of SIRT1 and Its Roles in Inflammation.

Authors:  Yunshu Yang; Yang Liu; Yunwei Wang; Yongyi Chao; Jinxin Zhang; Yanhui Jia; Jun Tie; Dahai Hu
Journal:  Front Immunol       Date:  2022-03-11       Impact factor: 7.561

4.  SIRT1 activity orchestrates ECM expression during hESC-chondrogenic differentiation.

Authors:  Christopher A Smith; Paul A Humphreys; Nicola Bates; Mark A Naven; Stuart A Cain; Mona Dvir-Ginzberg; Susan J Kimber
Journal:  FASEB J       Date:  2022-05       Impact factor: 5.834

5.  CSAG2 is a cancer-specific activator of SIRT1.

Authors:  Xu Yang; Patrick Ryan Potts
Journal:  EMBO Rep       Date:  2020-08-05       Impact factor: 8.807

6.  BET Inhibition Upregulates SIRT1 and Alleviates Inflammatory Responses.

Authors:  Tarja Kokkola; Tiina Suuronen; Maija Pesonen; Panagis Filippakopoulos; Antero Salminen; Elina M Jarho; Maija Lahtela-Kakkonen
Journal:  Chembiochem       Date:  2015-08-13       Impact factor: 3.164

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.